can fite biopharma (canfy) is a biotechnology company based out of 10 bareket street, פ"ת, israel.
Company profile
Ticker
CANF
Exchange
Website
CEO
Pnina Fishman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CANF stock data
Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
28 Mar 24
6-K
Can-Fite Reports 2023 Financial Results and Clinical Update
28 Mar 24
6-K
Report of Foreign Private Issuer
11 Mar 24
6-K
Patent has already been issued in other major markets including the U.S., EU, Japan and China
28 Feb 24
6-K
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
30 Jan 24
6-K
Piclidenoson is a small molecule safe oral drug suitable for the chronic treatment of patients who suffer from moderate to severe plaque psoriasis
29 Jan 24
EFFECT
Notice of effectiveness
8 Jan 24
CORRESP
Correspondence with SEC
3 Jan 24
F-3/A
Shelf registration (foreign) (amended)
28 Dec 23
6-K
Robust support for Namodenoson’s potential development as an anti-obesity drug, a projected $100 billion market by 2030
20 Dec 23
Transcripts
Latest ownership filings
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
CVI Investments, Inc.
14 Feb 22
SC 13G/A
INTRACOASTAL CAPITAL, LLC
11 Feb 22
SC 13G/A
Hudson Bay Capital Management LP
4 Feb 22
SC 13G/A
CVI Investments, Inc.
16 Feb 21
SC 13G/A
Hudson Bay Capital Management LP
9 Feb 21
SC 13G/A
INTRACOASTAL CAPITAL, LLC
29 Jan 21
SC 13G
ARMISTICE CAPITAL, LLC
19 Jun 20
SC 13G
CVI Investments, Inc.
19 Jun 20
SC 13G
Can-Fite BioPharma Ltd.
20 Feb 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 1 |
Closed positions | 3 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 218.46 mm |
Total shares | 62.71 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 39.50 mm | $50.95 mm |
CVI Investments | 23.16 mm | $0.00 |
MS Morgan Stanley | 33.31 k | $102.25 mm |
Rhumbline Advisers | 17.10 k | $52.51 mm |
FITB Fifth Third Bancorp | 3.00 k | $9.21 mm |
National Bank of Canada | 600.00 | $1.84 mm |
C Citigroup | 553.00 | $1.70 mm |
Proequities | 0.00 | $0.00 |
Press releases
Can-Fite Reports 2023 Financial Results and Clinical Update
28 Mar 24
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
11 Mar 24
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
28 Feb 24
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
30 Jan 24